Associated Genetic Biomarkers
CDKN2C Deletion is present in 0.01% of AACR GENIE cases, with colorectal adenocarcinoma, duodenal adenocarcinoma, large cell neuroendocrine carcinoma, malignant glioma, and oligodendroglioma having the greatest prevalence .
CDKN2C Deletion serves as an inclusion eligibility criterion in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain CDKN2C Deletion as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
Trials with CDKN2C Deletion in the inclusion eligibility criteria most commonly target glioblastoma, glioma, meningioma, and multiple myeloma .
Abemaciclib, cobimetinib, daratumumab, dexamethasone, and enasidenib are the most frequent therapies in trials with CDKN2C Deletion as an inclusion criteria .
Significance of CDKN2C Deletion in Diseases
CDKN2C is mutated in 5.05% of glioblastoma patients with CDKN2C Deletion present in 0.07% of all glioblastoma patients .
CDKN2C Deletion is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C Deletion and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) .
Multiple Myeloma +
CDKN2C Deletion is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C Deletion and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Abemaciclib, cobimetinib, and daratumumab are the most frequent therapies in trials for multiple myeloma that contain CDKN2C Deletion .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.